Fulcrum Therapeutics, Inc. – NASDAQ:FULC
Fulcrum Therapeutics stock price today
$6.41
+1.62
+33.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Fulcrum Therapeutics stock price monthly change
-40.20%
month
Fulcrum Therapeutics stock price quarterly change
-40.20%
quarter
Fulcrum Therapeutics stock price yearly change
-29.04%
year
Fulcrum Therapeutics key metrics
Market Cap | 236.79M |
Enterprise value | 90.80M |
P/E | -1.19 |
EV/Sales | 14.31 |
EV/EBITDA | -0.84 |
Price/Sales | 17.73 |
Price/Book | 0.56 |
PEG ratio | 0.18 |
EPS | -1.6 |
Revenue | N/A |
EBITDA | -110.47M |
Income | -99.42M |
Revenue Q/Q | -100% |
Revenue Y/Y | -37.94% |
Profit margin | -1732.43% |
Oper. margin | -1767.52% |
Gross margin | 0% |
EBIT margin | -1767.52% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFulcrum Therapeutics stock price history
Fulcrum Therapeutics stock forecast
Fulcrum Therapeutics financial statements
| Jun 2023 | 880K | -23.78M | -2702.61% |
|---|---|---|---|
| Sep 2023 | 759K | -24.01M | -3164.3% |
| Dec 2023 | 871K | -24.75M | -2842.25% |
| Mar 2024 | 0 | -26.87M |
| Mar 2024 | 0 | -26.87M | |
|---|---|---|---|
| Sep 2025 | 786.43K | -30.93M | -3933.64% |
| Oct 2025 | 0 | -39.66M | |
| Dec 2025 | 0 | -37.19M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 300332000 | 24.90M | 8.29% |
|---|---|---|---|
| Sep 2023 | 278879000 | 23.41M | 8.4% |
| Dec 2023 | 257694000 | 22.50M | 8.73% |
| Mar 2024 | 232588000 | 18.99M | 8.17% |
| Jun 2023 | -20.78M | 19.87M | 142K |
|---|---|---|---|
| Sep 2023 | -22.90M | 19.02M | 117.83M |
| Dec 2023 | -23.15M | 18.35M | 287K |
| Mar 2024 | -25.28M | 38.12M | 1.65M |
Fulcrum Therapeutics alternative data
| Aug 2023 | 89 |
|---|---|
| Sep 2023 | 89 |
| Oct 2023 | 89 |
| Nov 2023 | 89 |
| Dec 2023 | 89 |
| Jan 2024 | 89 |
| Feb 2024 | 89 |
| Mar 2024 | 76 |
| Apr 2024 | 76 |
| May 2024 | 76 |
| Jun 2024 | 76 |
| Jul 2024 | 76 |
Fulcrum Therapeutics other data
100.00%
+1.90%
of FULC is owned by hedge funds
50.76M
+10.89M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 43360 | 4884 |
| May 2024 | 0 | 236 |
| Patent |
|---|
Application Filling date: 18 Feb 2021 Issue date: 26 May 2022 |
Application Filling date: 12 Nov 2021 Issue date: 5 May 2022 |
Application Filling date: 20 Nov 2019 Issue date: 20 Jan 2022 |
Grant Filling date: 24 Apr 2020 Issue date: 13 Apr 2021 |
Application Filling date: 21 Jan 2020 Issue date: 10 Dec 2020 |
Application Filling date: 24 Apr 2020 Issue date: 19 Nov 2020 |
Application Filling date: 5 Oct 2018 Issue date: 22 Oct 2020 |
Grant Filling date: 19 Nov 2018 Issue date: 21 Jan 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 5 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Fulcrum Therapeutics stock today?
One share of Fulcrum Therapeutics stock can currently be purchased for approximately $6.41.
-
When is Fulcrum Therapeutics's next earnings date?
Unfortunately, Fulcrum Therapeutics's (FULC) next earnings date is currently unknown.
-
Does Fulcrum Therapeutics pay dividends?
No, Fulcrum Therapeutics does not pay dividends.
-
How much money does Fulcrum Therapeutics make?
Fulcrum Therapeutics has a market capitalization of 236.79M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 55.77% to 2.81M US dollars.
-
What is Fulcrum Therapeutics's stock symbol?
Fulcrum Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FULC".
-
What is Fulcrum Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Fulcrum Therapeutics?
Shares of Fulcrum Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Fulcrum Therapeutics's key executives?
Fulcrum Therapeutics's management team includes the following people:
- Mr. Bryan E. Stuart Pres, Chief Executive Officer & Director(age: 49, pay: $598,400)
- Mr. Curtis G. Oltmans J.D. Senior Vice President, Gen. Counsel & Corporation Sec.(age: 62, pay: $83,980)
- Mr. Mark J. Levin Executive Chairman(age: 75, pay: $73,000)
-
How many employees does Fulcrum Therapeutics have?
As Jul 2024, Fulcrum Therapeutics employs 76 workers.
-
When Fulcrum Therapeutics went public?
Fulcrum Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 18 Jul 2019.
-
What is Fulcrum Therapeutics's official website?
The official website for Fulcrum Therapeutics is fulcrumtx.com.
-
Where are Fulcrum Therapeutics's headquarters?
Fulcrum Therapeutics is headquartered at 26 Landsdowne Street, Cambridge, MA.
-
How can i contact Fulcrum Therapeutics?
Fulcrum Therapeutics's mailing address is 26 Landsdowne Street, Cambridge, MA and company can be reached via phone at +61 76518851.
Fulcrum Therapeutics company profile:
Fulcrum Therapeutics, Inc.
fulcrumtx.comExchange:
NASDAQ
Full time employees:
76
Industry:
Biotechnology
Sector:
Healthcare
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
26 Landsdowne Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001680581
ISIN: US3596161097
CUSIP: 359616109
